Understanding the Auditory Effects of Cancer Therapy

Understanding the Auditory Effects of Cancer Therapy

Cancer therapies have transformed patient outcomes, but some treatments can affect more than the disease itself. Certain chemotherapy agents, radiation therapy, and supportive medications have been associated with hearing loss, tinnitus, and balance disorders that may develop during or after treatment.

As cancer survival rates continue to improve, preserving quality of life has become an increasingly important part of comprehensive care. Recognizing treatment-related hearing changes early allows patients and providers to better manage their long-term health and communication needs.

At Johnson Audiology, we work alongside healthcare providers to monitor hearing throughout the cancer care journey. Early evaluation, ongoing monitoring, and intervention, when needed, can help patients maintain communication, independence, and quality of life before, during, and after treatment.

If your oncologist does not mention hearing testing as part of standard treatment protocol, bring up the subject yourself and request a referral to Johnson Audiology. It is wise to get a hearing test before treatment begins, midway through, and months, or even years, later.

What is ototoxicity and why does it matter?

Ototoxicity refers to damage caused by medications or treatments that affect the inner ear or auditory nerve. Depending on the therapy, patients may experience hearing loss, tinnitus, dizziness, or balance problems that interfere with communication and daily activities. Recognizing ototoxicity early allows healthcare providers to discuss treatment options, monitor hearing over time, and implement strategies that help minimize its long-term impact whenever possible.

Which cancer treatments are most likely to affect hearing?

While many cancer treatments are safe for hearing, certain therapies are known to carry a higher risk of auditory complications. Platinum-based chemotherapy drugs, such as cisplatin and carboplatin, are among the most common causes of treatment-related hearing loss. Radiation therapy involving the head and neck may also affect hearing, particularly when the inner ear is exposed. Understanding these risks allows patients and providers to monitor hearing more closely throughout treatment.

Are some cancer treatment medications retained in the cochlea?

Yes. While chemotherapy drugs are not typically held in the cochlea indefinitely, research suggests that cisplatin may remain in cochlear tissues for an extended period, perhaps months to years, even after treatment ends. This prolonged exposure can potentially contribute to ongoing damage even after treatment ends. This can cause permanent damage to the delicate sensory cells and structures within the inner ear. causing hearing loss.  Mammals are born with a lifetime supply of these sensory hair cells; once they are destroyed, they do not regenerate. The degree of hearing loss varies among individuals and depends on factors such as drug type, dosage, treatment duration, age, and overall health.

Why are some cancer treatment medications retained in the cochlea?

Much like the brain, the inner ear has a specialized barrier, called the Blood Labyrinth Barrier, that regulates what gets in. However, while it allows cisplatin-based chemotherapy drugs to enter the cochlea, it prevents the drug from easily exiting. Unlike other organs that flush out toxins, the cochlea lacks the biological machinery to clear out these heavy metals found in chemo drugs. The drug concentrates most heavily in the stria vascularis—the part of the inner ear responsible for maintaining inner ear fluid. 

How do inflammatory and autoimmune processes affect hearing?

Cancer and its treatments can trigger inflammatory and immune responses that may affect the delicate structures of the inner ear. In some patients, inflammation or immune-mediated damage can contribute to hearing loss, tinnitus, or balance disorders, either during treatment or as a delayed effect. While these complications are not common for every patient, understanding their potential impact highlights the importance of recognizing new auditory symptoms and pursuing timely evaluation when changes occur.

Can early monitoring help preserve hearing during treatment?

Baseline hearing evaluations followed by periodic monitoring can identify hearing changes before they become more noticeable or disruptive. This information helps patients and healthcare providers make informed decisions about treatment, rehabilitation, and ongoing hearing care. Even when treatment cannot be altered, early detection allows patients to receive timely support that may lessen the long-term impact of hearing loss and improve communication throughout their cancer journey. Cancer can alter a person's life in a host of ways with little a patient can do to change that fact. Because hearing loss is treatable with an array of technology, decreased hearing and diminished communication is something within a cancer patient's control and one less thing cancer can take from an individual.

Should hearing be monitored before, during, and after treatment?

Hearing monitoring plays an important role in identifying treatment-related changes before they significantly impact communication and quality of life. A baseline hearing evaluation establishes a reference point prior to treatment, while periodic assessments during and after therapy can detect subtle changes that might otherwise go unnoticed. Early identification allows patients and healthcare providers to make informed decisions, implement appropriate interventions, and better manage the long-term effects of cancer therapy on hearing.

How can treatment-related hearing loss affect quality of life?

Hearing loss can make conversations more difficult, increase listening effort, and reduce participation in social activities during an already challenging time. Patients may also struggle to understand healthcare instructions or communicate changes in their symptoms. Addressing hearing concerns early helps support effective communication, strengthens patient-provider relationships, and contributes to a better overall quality of life throughout cancer treatment and recovery.